MIRA PHARMACEUTICALS INC. Aktie

MIRA Pharmaceuticals released 7-day toxicology and toxicokinetic studies of the oral candidate MIRA-55 in rats and dogs. The studies provided dose-finding data and confirmed systemic exposure, with rats showing greater sensitivity and dogs greater tolerance. The company plans to use the results to prepare GLP-compliant follow-up studies and aims to submit an IND to the FDA in Q1 2027, provided all regulatory studies are successfully completed. » Plus sur de.investing.com

MIRA Pharmaceuticals has completed exploratory, non‑GLP-compliant 7-day toxicology and toxicokinetic repeat-dose studies for the drug candidates MIRA-55 and SKNY-1 in rats and dogs. Sample analyses, toxicokinetic evaluation and histopathology are still ongoing. MIRA-55 is being developed orally for chronic inflammatory pain, SKNY-1 for obesity and addictive disorders; both programs have also advanced through CMC and formulation optimization. The results are intended to inform study design and dose selection for future GLP-compliant, IND‑relevant studies. » Plus sur de.investing.com

MIRA Pharmaceuticals has selected a lead oral formulation of MIRA-55 in preclinical studies that showed systemic bioavailability after oral dosing and distribution into brain and liver tissue. The tissue exposure could modulate central pain-processing pathways and support peripheral anti-inflammatory effects; the DEA does not classify MIRA-55 as a controlled substance. The stock is trading near its 52-week low; the company is unprofitable but has more cash than debt and a market capitalization of $38.66 million. » Plus sur de.investing.com